Raymond James & Associates Seres Therapeutics, Inc. Transaction History

Raymond James & Associates

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 25, 2023	BUY	$4.67 - $6.55 $46,942 - $65,840	10,052 New	10,052 $48,000
Q3 2022 Oct 25, 2022	BUY	$3.5 - $7.2 $5,040 - $10,368	1,440 Added 7.62%	20,330 $131,000
Q2 2022 Aug 12, 2022	BUY	$2.7 - $7.62 $51,003 - $143,941	18,890 New	18,890 $65,000
Q3 2021 Nov 02, 2021	SELL	$5.46 - $22.6 $72,088 - $298,387	-13,203 Closed	0 $0
Q2 2021 Aug 11, 2021	BUY	$18.46 - $24.36 $243,727 - $321,625	13,203 New	13,203 $315,000
Q3 2020 Nov 04, 2020	SELL	$3.74 - $28.74 $56,784 - $436,359	-15,183 Closed	0 $0
Q2 2020 Jul 28, 2020	BUY	$3.04 - $6.2 $46,156 - $94,134	15,183 New	15,183 $72,000

41M

304K

471K

Ticker MCRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,072,000
Market Cap $104M
Description
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.